Intellia Therapeutics Inc(NTLA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NTLA Intellia Therapeutics Inc

已收盘 03-14 16:00:00 EDT

9.14

-0.08

-0.87%

盘后9.18

+0.04+0.44%

19:55 EDT

最高9.60	最低8.97	成交量206.42万
今开9.17	昨收9.22	日振幅6.83%
总市值9.46亿	流通市值8.98亿	总股本1.04亿
成交额1,900万	换手率2.10%	流通股本9,822万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NTLA","market":"US","secType":"STK","nameCN":"Intellia Therapeutics Inc","latestPrice":9.14,"timestamp":1741982400000,"preClose":9.22,"halted":0,"volume":2064223,"hourTrading":{"tag":"盘后","latestPrice":9.18,"preClose":9.14,"latestTime":"19:55 EDT","volume":78817,"amount":720512.4252,"timestamp":1741996556635},"delay":0,"floatShares":98219599,"shares":103517460,"eps":-5.250644,"marketStatus":"已收盘","change":-0.08,"latestTime":"03-14 16:00:00 EDT","open":9.17,"high":9.5999,"low":8.97,"amount":19004845.9998285,"amplitude":0.068319,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.250644,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1742198400000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1462507200000,"exchange":"NASDAQ","adjPreClose":9.22,"preHourTrading":{"tag":"盘前","latestPrice":9.51,"preClose":9.22,"latestTime":"08:56 EDT","volume":3064,"amount":29133.513928,"timestamp":1741956969384},"postHourTrading":{"tag":"盘后","latestPrice":9.18,"preClose":9.14,"latestTime":"19:55 EDT","volume":78817,"amount":720512.4252,"timestamp":1741996556635},"volumeRatio":0.782969,"impliedVol":1.5757,"impliedVolPercentile":0.996},"requestUrl":"/m/hq/s/NTLA/wiki","defaultTab":"wiki","newsList":[{"id":"2519837794","title":"Intellia Therapeutics, Inc.盘中异动 快速上涨5.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2519837794","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2519837794?lang=zh_cn&edition=full","pubTime":"2025-03-13 21:42","pubTimestamp":1741873350,"startTime":"0","endTime":"0","summary":"北京时间2025年03月13日21时42分，Intellia Therapeutics, Inc.股票出现异动，股价快速上涨5.20%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.90%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics 是一家基因编辑公司，致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系，以推进其产品线的发展，其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250313214230ab640731&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1861558580.USD","BK4535","LENZ","BK4588","BK4139","BK4556","NTLA","BK4585","LU1861559042.SGD"],"gpt_icon":0},{"id":"2518728908","title":"Intellia Therapeutics, Inc.盘中异动 大幅下挫5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518728908","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518728908?lang=zh_cn&edition=full","pubTime":"2025-03-11 22:47","pubTimestamp":1741704439,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日22时47分，Intellia Therapeutics, Inc.股票出现异动，股价急速下挫5.06%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为2.13%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics 是一家基因编辑公司，致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系，以推进其产品线的发展，其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311224720a1d5370d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4556","BK4588","BK4585","NTLA","LU1861559042.SGD","BK4535","LU1861558580.USD","BK4139","LENZ"],"gpt_icon":0},{"id":"2518272482","title":"Intellia Therapeutics, Inc.盘中异动 早盘快速跳水5.12%报9.82美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518272482","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518272482?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:32","pubTimestamp":1741613523,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时32分，Intellia Therapeutics, Inc.股票出现异动，股价大幅下跌5.12%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.18%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics 是一家基因编辑公司，致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系，以推进其产品线的发展，其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213203abf2fc32&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4556","LENZ","BK4535","BK4585","BK4588","LU1861559042.SGD","BK4139","LU1861558580.USD","NTLA"],"gpt_icon":0},{"id":"2517458483","title":"Intellia Therapeutics, Inc.2024财年实现净利润-5.19亿美元，同比减少7.90%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517458483","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517458483?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363240,"startTime":"0","endTime":"0","summary":"3月8日，Intellia Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-5.19亿美元，同比减少7.90%；其中营业收入为57.88百万美元，同比增加59.54%，每股基本收益为-5.25美元。从资产负债表来看，Intellia Therapeutics, Inc.总负债3.19亿美元，其中短期债务20.25百万美元，资产负债比为3.74，流动比率为5.77。机构评级：截至2025年3月8日，当前有24家机构对Intellia Therapeutics, Inc.目标价做出预测，其中目标均价为42.54美元，其中最低目标价为9.00美元，最高目标价为106.00美元。Intellia 致力于利用这项技术治疗基因定义的疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000117abed65f5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NTLA","LENZ"],"gpt_icon":0},{"id":"2517166011","title":"Intellia Therapeutics, Inc.盘中异动 早盘急速下挫5.18%报8.88美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517166011","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517166011?lang=zh_cn&edition=full","pubTime":"2025-03-06 22:35","pubTimestamp":1741271743,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日22时35分，Intellia Therapeutics, Inc.股票出现异动，股价大幅跳水5.18%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.62%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics 是一家基因编辑公司，致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系，以推进其产品线的发展，其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223543989eb532&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4556","BK4588","LU1861559042.SGD","BK4585","BK4535","LENZ","LU1861558580.USD","BK4139","NTLA"],"gpt_icon":0},{"id":"2517153059","title":"Intellia Therapeutics(NTLA.US)获HC Wainwright & Co.首次覆盖，给予买入评级, 目标价30.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517153059","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517153059?lang=zh_cn&edition=full","pubTime":"2025-03-05 20:11","pubTimestamp":1741176665,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics(NTLA.US)获HC Wainwright & Co.首次覆盖，给予买入评级, 目标价30.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/05201148546317.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","NTLA"],"gpt_icon":0},{"id":"2516657315","title":"Intellia Therapeutics, Inc.盘中异动 大幅下挫5.00%报9.59美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516657315","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516657315?lang=zh_cn&edition=full","pubTime":"2025-03-04 02:46","pubTimestamp":1741027611,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日02时46分，Intellia Therapeutics, Inc.股票出现异动，股价快速跳水5.00%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.59%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics 是一家基因编辑公司，致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系，以推进其产品线的发展，其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304024651989a4900&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4556","BK4588","LU1861559042.SGD","BK4585","BK4535","LENZ","LU1861558580.USD","BK4139","NTLA"],"gpt_icon":0},{"id":"2516032763","title":"花旗：维持Intellia Therapeutics(NTLA.US)评级，由中性调整至中性评级, 目标价由12.00美元调整至14.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516032763","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516032763?lang=zh_cn&edition=full","pubTime":"2025-03-01 03:21","pubTimestamp":1740770487,"startTime":"0","endTime":"0","summary":"花旗：维持Intellia Therapeutics(NTLA.US)评级，由中性调整至中性评级, 目标价由12.00美元调整至14.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/01032148470157.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["NTLA","LENZ"],"gpt_icon":0},{"id":"2516773673","title":"富国银行：维持Intellia Therapeutics(NTLA.US)评级，由增持调整至增持评级, 目标价由60.00美元调整至50.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516773673","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516773673?lang=zh_cn&edition=full","pubTime":"2025-03-01 01:31","pubTimestamp":1740763885,"startTime":"0","endTime":"0","summary":"富国银行：维持Intellia Therapeutics(NTLA.US)评级，由增持调整至增持评级, 目标价由60.00美元调整至50.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/01013148469989.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","NTLA"],"gpt_icon":0},{"id":"1148276056","title":"异动解读 | 投资机构下调评级和目标价,Intellia Therapeutics盘中股价大跌5.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1148276056","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148276056?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:39","pubTimestamp":1740753566,"startTime":"0","endTime":"0","summary":"基因编辑公司Intellia Therapeutics今日盘中股价大跌5.8%,引起了市场的广泛关注。根据报道,这次股价下跌与多家投资银行对Intellia Therapeutics投资评级和目标价进行下调有关。作为一家处于发展期的基因编辑科技公司,Intellia Therapeutics产品线仍待丰富,商业化前景存有不确定性。分析人士普遍对该公司发展前景持谨慎态度,并下调投资评级及目标价来反映他们对公司长期价值的重新评估。这直接打击了市场对NTLA未来前景的预期,推动当天公司股价出现大幅下跌。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NTLA"],"gpt_icon":0},{"id":"2514932007","title":"Intellia Therapeutics, Inc.盘中异动 股价大跌5.66%报10.25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514932007","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514932007?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:31","pubTimestamp":1740753092,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时31分，Intellia Therapeutics, Inc.股票出现波动，股价快速跳水5.66%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.02%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics 是一家基因编辑公司，致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系，以推进其产品线的发展，其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223132a25800fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","LENZ","LU1861558580.USD","BK4139","NTLA","BK4556","LU1861559042.SGD","BK4585","BK4535"],"gpt_icon":0},{"id":"1158237633","title":"异动解读 | 基因编辑公司Intellia Therapeutics盘前股价大跌5.06%,投资评级遭下调成为主因","url":"https://stock-news.laohu8.com/highlight/detail?id=1158237633","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158237633?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:30","pubTimestamp":1740753034,"startTime":"0","endTime":"0","summary":"基因编辑公司Intellia Therapeutics今日盘前股价大跌5.06%,引起了市场的广泛关注。分析人士认为,投行下调该公司投资评级成为主要原因。据报道,投资银行摩根士丹利将Intellia Therapeutics的评级由\"增持\"下调至\"中性\",目标股价也由45美元大幅下调至13美元。分析师普遍对该公司的发展前景看空,导致下调评级和目标价。作为一家从事基因编辑技术研发和应用的科技公司,Intellia目前仍处于培育期,产品线有待丰富。未来能否顺利进入商业化阶段仍存在不确定性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | 基因编辑公司Intellia Therapeutics盘前股价大跌5.06%,投资评级遭下调成为主因","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NTLA"],"gpt_icon":0},{"id":"2514132809","title":"小摩：下调Intellia Therapeutics(NTLA.US)评级，由增持调整至中性评级, 目标价由45.00美元调整至13.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514132809","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514132809?lang=zh_cn&edition=full","pubTime":"2025-02-28 19:58","pubTimestamp":1740743894,"startTime":"0","endTime":"0","summary":"小摩：下调Intellia Therapeutics(NTLA.US)评级，由增持调整至中性评级, 目标价由45.00美元调整至13.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/28195848463646.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","NTLA"],"gpt_icon":0},{"id":"1161094475","title":"异动解读 | NTLA发布佳绩财报 股价盘中大涨8.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=1161094475","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161094475?lang=zh_cn&edition=full","pubTime":"2025-02-27 23:12","pubTimestamp":1740669120,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics Inc今日盘中大涨8.06%,引发了市场广泛关注。导致此次股价上涨的主要原因是该公司发布了令人鼓舞的2024年第四季度财报数据。根据最新财报,NTLA在2024年第四季度录得销售额1287万美元,高于分析师预期的853万美元,同比去年增长771.57%。作为一家基因编辑公司,NTLA专注于开发治疗基因定义疾病的CRISPR/Cas9疗法,具有广阔的发展前景。因此在机构看来,NTLA长期增长潜力巨大,多数分析师对其持偏好评级。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NTLA"],"gpt_icon":0},{"id":"2514338562","title":"Intellia Therapeutics, Inc.盘中异动 早盘大幅上涨5.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514338562","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514338562?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:32","pubTimestamp":1740666724,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时32分，Intellia Therapeutics, Inc.股票出现异动，股价急速上涨5.60%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.31%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics 是一家基因编辑公司，致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系，以推进其产品线的发展，其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502272232059895101f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1861558580.USD","BK4535","LENZ","BK4588","BK4139","BK4556","NTLA","BK4585","LU1861559042.SGD"],"gpt_icon":0},{"id":"1185918142","title":"Intellia Therapeutics 2024年第四季度GAAP每股亏损$1.27，优于预期的$1.36，销售额为1287万美元，优于预期的853万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1185918142","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185918142?lang=zh_cn&edition=full","pubTime":"2025-02-27 20:38","pubTimestamp":1740659915,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics报告季度每股亏损1.27美元，优于分析师预期的亏损1.36美元，增幅为6.62%。这相比去年同期每股亏损1.46美元，增加了13.01%。以上内容来自Benzinga Earnings专栏，原文如下：Intellia $Therapeutics$  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 6.62 percent. This is a 13.01 percent increase over losses of $ per share from the same period last year.  The company reported quarterly sales of $12.87 million which beat the analyst consensus estimate of $8.53 million by 50.89 percent.  This is a 771.57 percen","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Intellia Therapeutics 2024年第四季度GAAP每股亏损$1.27，优于预期的$1.36，销售额为1287万美元，优于预期的853万美元","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTLA"],"gpt_icon":1},{"id":"2514007773","title":"Intellia Therapeutics, Inc.盘中异动 早盘快速下挫5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514007773","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514007773?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:46","pubTimestamp":1740411993,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时46分，Intellia Therapeutics, Inc.股票出现波动，股价快速跳水5.00%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.20%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics 是一家基因编辑公司，致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系，以推进其产品线的发展，其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224234633abdb1f9e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","NTLA","LU1861559042.SGD","LU1861558580.USD","BK4588","BK4556","BK4585","BK4535"],"gpt_icon":0},{"id":"2512833914","title":"Intellia Therapeutics, Inc.盘中异动 急速拉升5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512833914","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512833914?lang=zh_cn&edition=full","pubTime":"2025-02-19 22:37","pubTimestamp":1739975820,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日22时37分，Intellia Therapeutics, Inc.股票出现异动，股价大幅上涨5.03%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.01%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics 是一家基因编辑公司，致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系，以推进其产品线的发展，其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502192237009628ce54&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4556","LENZ","LU1861558580.USD","NTLA","LU1861559042.SGD","BK4139","BK4585","BK4588","BK4535"],"gpt_icon":0},{"id":"2512165128","title":"Intellia Therapeutics, Inc.盘中异动 早盘急速拉升5.33%报11.27美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512165128","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512165128?lang=zh_cn&edition=full","pubTime":"2025-02-18 22:32","pubTimestamp":1739889136,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日22时32分，Intellia Therapeutics, Inc.股票出现异动，股价急速拉升5.33%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.11%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics 是一家基因编辑公司，致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系，以推进其产品线的发展，其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218223216abd3af4b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","NTLA","LU1861559042.SGD","LU1861558580.USD","BK4588","BK4556","BK4585","BK4535"],"gpt_icon":0},{"id":"2511988257","title":"Will Intellia Therapeutics (NASDAQ:NTLA) Spend Its Cash Wisely?","url":"https://stock-news.laohu8.com/highlight/detail?id=2511988257","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511988257?lang=zh_cn&edition=full","pubTime":"2025-02-15 22:52","pubTimestamp":1739631177,"startTime":"0","endTime":"0","summary":"Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"Intellia Therapeutics（纳斯达克股票代码：NTLA）会明智地使用现金吗？","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/will-intellia-therapeutics-nasdaqntla-spend-its-cash-wisely","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MNQmain","BK4112","IE00BKPKM429.USD","NVIW.SI","PSQ","LU2210150020.SGD","NTLA","QID",".IXIC","BK4585","IE00BGHQF748.EUR","NDAQ","IE00B3QW5Z07.USD","NQmain","IE00B64PRP62.GBP","BK4535","USAW.SI","TSYW.SI","LU2095319765.USD","BK4556","BK4588","LU2210149790.SGD","LU1861559042.SGD","USJW.SI","TQQQ","LU1861558580.USD","QLD","BK4139","SQQQ"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.intelliatx.com","stockEarnings":[{"period":"1week","weight":-0.0687},{"period":"1month","weight":0.0011},{"period":"3month","weight":-0.2853},{"period":"6month","weight":-0.5822},{"period":"1year","weight":-0.6784},{"period":"ytd","weight":-0.2093}],"compareEarnings":[{"period":"1week","weight":-0.0372},{"period":"1month","weight":-0.089},{"period":"3month","weight":-0.0874},{"period":"6month","weight":-0.0188},{"period":"1year","weight":0.0687},{"period":"ytd","weight":-0.0591}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Intellia Therapeutics, Inc.于2014年5月在特拉华州注册成立。该公司是一家领先的基因编辑公司，专注于利用最近开发的被称为CRISPR/ Cas9的系统生物工具进行的独特的、潜在治愈疗法的发展。公司认为CRISPR/ Cas9技术具有通过单一疗程永久编辑疾病相关的基因在人体内进行改造药物的潜力。该公司打算利用其领先的科学专业知识、临床开发经验和知识产权地位解锁CRISPR/ Cas9基因编辑广泛的治疗应用，发展有潜能的新一代治疗产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":0.000449},{"month":2,"riseRate":0.666667,"avgChangeRate":0.066917},{"month":3,"riseRate":0.222222,"avgChangeRate":-0.045229},{"month":4,"riseRate":0.375,"avgChangeRate":-0.074095},{"month":5,"riseRate":0.25,"avgChangeRate":0.030737},{"month":6,"riseRate":0.888889,"avgChangeRate":0.214578},{"month":7,"riseRate":0.555556,"avgChangeRate":0.022335},{"month":8,"riseRate":0.555556,"avgChangeRate":0.026121},{"month":9,"riseRate":0.111111,"avgChangeRate":-0.069902},{"month":10,"riseRate":0.222222,"avgChangeRate":-0.087409},{"month":11,"riseRate":0.666667,"avgChangeRate":0.118994},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.093181}],"exchange":"NASDAQ","name":"Intellia Therapeutics Inc","nameEN":"Intellia Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.31.7","shortVersion":"4.31.7","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Intellia Therapeutics Inc(NTLA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Intellia Therapeutics Inc(NTLA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Intellia Therapeutics Inc,NTLA,Intellia Therapeutics Inc股票,Intellia Therapeutics Inc股票老虎,Intellia Therapeutics Inc股票老虎国际,Intellia Therapeutics Inc行情,Intellia Therapeutics Inc股票行情,Intellia Therapeutics Inc股价,Intellia Therapeutics Inc股市,Intellia Therapeutics Inc股票价格,Intellia Therapeutics Inc股票交易,Intellia Therapeutics Inc股票购买,Intellia Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Intellia Therapeutics Inc(NTLA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Intellia Therapeutics Inc(NTLA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}